CEA Fast Test Kit (Immunofluorescence Assay)

CEA Fast Test Kit 

(Immunofluorescence Assay)

Intended Use

CEA Fast Test Kit (Immunofluorescence Assay) is intended for in vitro quantitative determination of carcinoembryonic antigen (CEA) in serum or plasma samples. This test can be used as a tumor marker to monitor colorectal carcinoma treatment and follow-up. But CEA test is not reliable for diagnosing cancer or as a screening test for early detection of cancer.

About CEA

CEA is a glycosylated molecule with a molecular weight of approximately 180,000 Daltons. CEA, like AFP, belongs to the group of carcino-fetal antigens that are produced during the embryonic and fetal period. The CEA gene family consists of about 17 active genes in two subgroups. The first group contains CEA and the nonspecific cross-reacting antigens (NCA); the second group contains the pregnancy-specific glycoproteins (PSG).

CEA is normally produced in gastrointestinal tissue during fetal development, but the production stops before birth. Consequently, CEA is usually present at very low levels in the blood of healthy adults. Slight to moderate CEA elevations can also occur in 20-50% non-malignant diseases of the intestine, the pancreas, the liver, and the lungs (i.e. liver cirrhosis, chronic hepatitis, pancreatitis, ulcerative colitis, Crohn's Disease). Smoking can also lead to elevated CEA values and needs to be taken into account when interpreting CEA levels.

CEA determinations are not recommended for cancer screening in the general population and CEA concentrations within the normal range do not exclude the possible presence of a malignant disease.

Contents

For Getein1100

Package specifications: 10 tests/box, 25 tests/box

1) Getein CEA test card in a sealed pouch with desiccant.

2) Disposable pipet

3) User Manual:1 piece/box

4) SD card: 1 piece/box

Note: Do not mix or interchange different batches of kits.

Specifications

Applicable Device

Getein1100 Immunofluorescence Quantitative Analyzer

Clinical Application

The main indication for CEA determinations is to monitor colorectal carcinoma treatment, to identify recurrences after treatment or surgical resection and to aid in staging and assessing metastasis.